An interventional study of tVNS and Sham in Healthy Participants, Anxiety Disorders (With High Anxiety Symptoms) and Depressive Disorders (With High Anhedonia Symptoms), sponsored by Dr. Nils B. Kroemer. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Dr. Nils B. Kroemer · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Anxiety Disorders with a site in Germany — 27 open to participants now, 30 under way, none of them phase 3. Anxiety Disorders · Germany.
Among the 133 studies in Anxiety Disorders with a site in Germany, this one is the 57th largest by planned enrollment of the 99 interventional ones that give a count, is one of 6 that started in 2026, is one of 76 with no phase, reaches primary completion later than 26 of the 29 other live ones, and was the 130th registered.
7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.
Browse Anxiety Disorders studies →27 of the 133 studies in Anxiety Disorders with a site in Germany are open now. Recruiting first, the newest first:
Goethe University · Sites in Germany
Ages 18–65
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · Sites in Germany
Ages 18–99 · Women only
Ruhr University of Bochum · Sites in Germany
Ages 18–65
Vera Guttenthaler · Sites in Germany
Ages 18+
Hannover Medical School · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 10 · Phase 4 3
First in 2001; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.
Median enrollment 138 across the 99 interventional studies, 629 across the 33 observational. Of the 89 that completed or were terminated, 5 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 133 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dr. Nils B. Kroemer as lead sponsor.
Dr. Nils B. Kroemer has 1 study filed under Anxiety Disorders — fewer than ten, so there is no comparison to draw.
11 of the studies in Anxiety Disorders with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07568093Hannover Medical SchoolPARO-agitation-study | 2026-12 |
| NCT07270445Vera GuttenthalerEffect of Virtual Reality Use on Preoperative Anxiety | 2026-12-14 |
| NCT07432945Ruhr University of BochumIn Vivo Exposure vs. Videochat-Based Vicarious Exposure | 2026-12-31 |
| NCT07110896dsm-firmenich Switzerland AGStudy Evaluating the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults | 2027-02 |
| NCT07065240Seaport TherapeuticsA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | 2027-03 |
Add all 11 to your calendar (.ics) → With an account.
Among the 133 studies in Anxiety Disorders with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates if anhedonia and anxiety symptoms are associated with alterations in reinforcement learning, effort trade-offs for wins vs. punishments, and foraging behavior under threat. Moreover, it will investigate whether these processes can be influenced by a metabolic load and/or transcutaneous vagus nerve stimulation (tVNS). The project consists of (a) an online reinforcement learning study, used to characterize learning, reward sensitivity, and meta-cognition, and (b) a laboratory study in which participants first undergo fMRI while completing an effort-based decision-making task. Second, participants will complete two sessions in VR with randomized active or sham tVNS during a foraging task before and after a caloric load with concurrent physiological recordings.
The overarching goal of this project is to investigate the potential of modulating internal signals in patients with mood and anxiety disorders to improve the balance between approach and avoidance behavior. To this end, tVNS (vs. sham) will be used to alter foraging behavior under threat.
To address the inherent heterogeneity of symptoms, it is planned to recruit participants with anxiety symptoms (ANX), anhedonia symptoms (ANH), both anxiety and mood symptoms (ANX+ANH), and healthy control participants (HCP). The groups will be matched for the group-average and distribution of age, sex, and BMI (age: 18 to 40 years, BMI 18.5 - 30 kg/m²). After an online assessment, diagnostic visit, and MRl-based phenotyping, internal signals are targeted with tVNS and a caloric load to shift the approach-avoidance behavior. In a randomized crossover study, participants will receive stimulation (tVNS or sham) in a hungry state (>4 h after the last meal at a time when they would typically have their next meal) and complete a VR-based foraging task under threat. They will then receive a standardized caloric load (milkshake containing \~400 kcal) and repeat the task with the same stimulation in a different metabolic state (postprandial). Crucially, participants can move freely during the task so that behavioral adaptations in response to threats (e.g., escaping a panther) as well as physiological adaptations (e.g., heart rate) and their recovery can be measured.
The study is split into three parts:
Hypotheses:
Enrollment:
In the online assessment, at least 250 participants will be included to investigate differences in learning from wins and losses and how well behavioral shifts align with self-evaluation of performance. The sample size allows detecting even small effects that are likely in psychiatric research (r = .20) with a high power (1-β = 0.89). If necessary, further participants will be recruited for the online sample until the planned sample of N=104 participants has completed the tVNS intervention. For the phenotyping and the subsequent intervention study, 104 participants from 4 groups combining low/high anxiety and low/high anhedonia will be reinvited. With this transdiagnostic approach, the effects of anhedonia and anxiety on approach-avoid behavior can be disentangled. Crucially, oversampling participants with either high or low symptoms will maximize the expected effect size. The sample allows for evaluation of medium correlations (r = .30) between symptoms and approach-avoid trade-offs with a power of 1-β = 0.89. For the tVNS intervention, a sample of 104 participants allows for the conclusive study of medium-sized effects (dz = .40) observed in previous work (Neuser et al., 2020) with very high power (1-β = 0.98) across the sample. Differences in the tVNS response between participants (medium effect size, r = .30) can be evaluated with a power of 1-β = 0.89.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The healthy control group will include participants without clinically relevant symptoms of anxiety or anhedonia. Inclusion criteria are a STICSA total score \<= 40 and a SHAPS total score below 23.5. Participants in this group must not meet the criteria for a current psychiatric diagnosis defined in the exclusion criteria, as confirmed by the Structured Clinical Interview for DSM (SCID).
Device: tVNS · Device: Sham
The anxiety group will include participants with elevated anxiety symptoms, defined as a STICSA total score \>= 43. All participants must meet diagnostic criteria for a current anxiety disorder or/and current depressive disorder, confirmed by the SCID.
Device: tVNS · Device: Sham
The anhedonia group will include participants with elevated anhedonia symptoms, defined as a SHAPS total score greater than 29.5. All participants must meet diagnostic criteria for a current depressive disorder or/and current anxiety disorder, confirmed by the SCID.
Device: tVNS · Device: Sham
The combined group will include participants with both elevated anxiety and anhedonia symptoms, defined as STICSA \>= 43 and SHAPS \> 29.5, respectively. All participants must meet diagnostic criteria for a current anxiety disorder or/and a current depressive disorder, confirmed by the SCID.
Device: tVNS · Device: Sham
The intervention consists of event-triggered tVNS in the form of short pulses (\~1-5s; frequency: 25Hz). A non-CE-certified and non-medical device (tVNS® R tVNS technologies, for research purposes) will be used. Stimulation intensity will be individually calibrated to ensure perceptible (mild pricking) but non-painful stimulation for each participant. The protocol is the same for all groups.
The sham condition similarly consists of event-triggered, closed-loop stimulation, but without vagus nerve activation (short pulses of 1-5s; frequency: 25Hz). A non-CE-certified and non-medical device (tVNS® R, for research purposes) will be used. The manufacturer is not involved in the study. Stimulation intensity will be individually calibrated to ensure perceptible (mild pricking) but non-painful stimulation for each participant. The protocol is the same for all groups.
Stimulation-induced changes in the number of rewards collected under threat (VR foraging task)
The number of rewards collected during a VR foraging task will be compared between stimulation conditions (tVNS vs. sham).
Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)
BOLD response during the effort-trade-off task (offer-phase)
The outcome describes task-evoked neural activation (BOLD response) during the offer phase of the effort trade-off task. Neural activation is measured as a task-evoked BOLD response during offer presentation.
Time frame: Collected during fMRI session (single session throughout study completion ~35min per participant)
Reward learning
Reward learning is repeatedly measured during an online bandit task with fluctuating reward probabilities. Reward learning behavior will be collected online in 10 runs spread over 5 to 10 days, each including 150 trials.
Time frame: Online task performance assessed online before lab-visits (approximately 10 days)
Metabolic state x stimulation-induced changes in the number of rewards collected under threat (VR task)
The number of rewards collected during a VR foraging task will be compared between two different metabolic states (fasted vs. postprandial) and stimulation conditions (tVNS vs. sham).
Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)
BOLD response during the effort-trade-off task (feedback-phase)
The outcome describes task-evoked neural activation (BOLD response) during the feedback phase of the effort trade-off task. Neural activation is measured as a task-evoked BOLD response during feedback presentation.
Time frame: Collected during fMRI session (single session throughout study completion ~35min per participant)
Choices in the effort trade-off task
Choices in the effort trade-off task will be assessed as a binary outcome of accept vs. reject.
Time frame: During a single fMRI session throughout study completion (approximately 3 weeks)
Association between BOLD response during the effort-trade-off task (offer-phase) and effort discounting
The primary outcome is the association (regression coefficient) quantifying the relationship between effort discounting and neural activation (BOLD response) during the offer-phase of an effort trade-off task. Neural activation is measured as a task-evoked BOLD response during offer presentation. Effort discounting is estimated from behavioral choices in the effort trade-off task using computational modeling.
Time frame: During a single fMRI session throughout study completion (approximately 3 weeks)
Association between BOLD response during the effort-trade-off task (feedback phase) and effort-discounting
The primary outcome is the association (regression coefficient) quantifying the relationship between effort-discounting and neural activation (BOLD response) during the feedback phase of an effort trade-off task. Neural activation is measured as task-evoked BOLD response during feedback presentation.Effort-discounting is estimated from behavioral choices in the effort trade-off task using computational modeling.
Time frame: During a single fMRI session throughout study completion (approximately 3 weeks)
Effort-discounting
The outcome describes effort-discounting derived from the effort trade-off task. Effort-discounting is estimated from behavioral choices in the effort trade-off task using computational modeling.
Time frame: During a single fMRI session throughout study completion (approximately 3 weeks)
Association between BOLD responses during effort trade-offs and number of rewards during VR
The primary outcome is the association (regression coefficient) quantifying the relationship between individual differences in foraging during VR and task-evoked neural connectivity. Task-evoked BOLD responses during the effort trade-off task is measured using functional magnetic resonance imaging (fMRI). Foraging in the VR task is the number of rewards collected.
Time frame: Neural data: During a single fMRI session throughout study completion (approximately 3 weeks); Behavioral data: During sham stimulation session throughout study completion (approximately 3 weeks)
Association between neural connectivity and number of rewards during VR
The primary outcome is the association (regression coefficient) quantifying the relationship between individual differences in effort-discounting and task-evoked neural connectivity. Task-evoked neural connectivity during the effort trade-off task is measured using functional magnetic resonance imaging (fMRI). Neural connectivity is quantified as region-of-interest-level functional connectivity. The number of rewards is measured in the VR foraging task.
Time frame: Neural data: During a single fMRI session throughout study completion (approximately 3 weeks); Behavioral data: During sham stimulation sessions throughout study completion (approximately 3 weeks)
Stimulation-induced changes in time spent foraging under threat (VR foraging task)
The primary outcome is the comparison of time spent foraging (seconds) during the VR foraging task between stimulation conditions (tVNS vs. sham).
Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)
Stimulation-induced changes in escape latency under threat (VR foraging task)
The primary outcome is the comparison of escape latency (seconds) during the VR foraging task between stimulation conditions (tVNS vs. sham).
Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)
Stimulation-induced changes in threat-evoked heart rate increase (VR foraging task)
The primary outcome is the comparison of heart rate increases following threat during the VR foraging task between active vs. sham tVNS. Autonomic responses to threat are operationalized as the change in heart rate from a pre-threat baseline period (safety period preceding the trial) to the first minute following threat onset.
Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)
Stimulation-induced changes in heart rate recovery following threat (VR foraging task)
The primary outcome is the comparison of heart rate recovery following threat response during the VR foraging task between stimulation conditions (tVNS vs. sham).
Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)
Stimulation-induced changes in habituation of heart rate responses following threat (VR foraging task)
The primary outcome is the comparison of habituation of heart rate response following threat over trials during the VR foraging task between active vs. sham tVNS.
Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)
Stimulation-induced changes in subjective metabolic state (VR foraging task)
The primary outcome is the comparison of the change in subjective metabolic state after receiving a caloric load between stimulation conditions (tVNS vs. sham). Subjective metabolic state assessed during a VR foraging task using 0-100 Visual Analog Scales (VAS) of hunger and satiety. A metabolic state score is calculated as the difference between hunger and satiety ratings, scaled from -1 to 1 ((hunger-satiety)/100). The difference will then be compared between stimulation conditions.
Time frame: During each stimulation session (tVNS vs. sham) throughout study completion (approximately 3 weeks)
Stimulation-induced changes in affect (PANAS)
The primary outcome is the comparison of affect between stimulation conditions (tVNS vs. sham). Affective state is assessed using the Positive and Negative Affect Schedule (PANAS), administered as Visual Analog Scales (0-100). A composite affect score (positive - negative affect) is calculated from positive and negative affect ratings.
Time frame: During each stimulation session (tVNS vs. sham) throughout study completion (approximately 3 weeks)
Metabolic state x stimulation-induced changes in affect (PANAS)
The primary outcome is the comparison of affect between metabolic state (fasted vs. postprandial) and stimulation condition (tVNS vs. sham). The primary analysis examines the interaction between metabolic state and stimulation condition. Affective state is assessed using the Positive and Negative Affect Schedule (PANAS), administered as Visual Analog Scales (0-100). A composite affect score (positive - negative affect) is calculated from positive and negative affect ratings.
Time frame: During each stimulation session (tVNS vs. sham) throughout study completion (approximately 3 weeks)
Metabolic state x stimulation-induced changes in time spent foraging under threat (VR task)
The primary outcome is the comparison of time spent foraging (seconds) during a VR foraging task between metabolic state (fasted vs. postprandial) and stimulation condition (tVNS vs. sham). The primary analysis examines the interaction between metabolic state and stimulation condition.
Time frame: During each stimulation session (active and sham) throughout study completion (approximately 3 weeks)
Metabolic state x stimulation-induced changes in escape latency under threat (VR task)
The primary outcome is the comparison of escape latency (seconds) during a VR foraging task between metabolic state (fasted vs. postprandial) and stimulation condition (tVNS vs. sham). The primary analysis examines the interaction between metabolic state and stimulation condition.
Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)
Response times in the online task
The outcome describes response times collected during the online task. Response times (milliseconds) are collected in trials of the online reward learning task (10 runs with 150 each).
Time frame: Assessed online before lab-visits (approximately 10 days)
Choice accuracy in the online task
Choice accuracy (binary correct vs. incorrect) is derived from trials of the online reward learning task (10 runs with 150 each).
Time frame: Assessed online before lab-visits (approximately 10 days)
Metacognitive calibration (performance-rating coupling)
The outcome describes metacognitive calibration in a reward learning task. Self-reported ratings are collected at the end of each run (10 runs) on a Visual Analog Scale (0-100 Visual Analog Scale) assessing subjective performance. Higher values represent better subjective performance. A metacognitive calibration score will be calculated as the difference between self-reported performance and objective task performance.
Time frame: Assessed online before lab-visits (approximately 10 days)
Ecological Momentary Assessments (EMA) for mood
The outcome describes a mood state score calculated from data collected during the online reward learning task. EMA questions (0-100 Visual Analog Scale) assessing mood state (happy and sad) will be asked before every run of the online task (10 runs). Mood state will be calculated as happy - sad.
Time frame: Assessed online before lab-visits (approximately 10 days)
Ecological Momentary Assessments (EMA) for stress
The outcome describes the stress rating of participants collected during the online reward learning task. EMA question (0-100 Visual Analog Scale) assessing subjective stress will be asked before every run of the online task (10 runs).
Time frame: Assessed online before lab-visits (approximately 10 days); EMA data: Collected before every online session (x 10)
Association between Ecological Momentary Assessments (EMA) and response times in the online task
The primary outcome is the association (regression coefficient) quantifying the relationship between mood state and response times. Response times (seconds) are derived from trials of the online reward learning task (10 runs with 150 trials each). EMA questions (0-100 Visual Analog Scale) assessing mood (happy - sad) are asked before every run of the online task (10 runs).
Time frame: Assessed online before lab-visits (approximately 10 days)
Association between BOLD response during the effort-trade-off task and tVNS-induced changes in the number of rewards collected
The primary outcome is the association (regression coefficient) quantifying the relationship between neural activity and behavioral tVNS response. tVNS response is defined as the within-subject change in the number of rewards collected during VR foraging under active vs sham tVNS. Neural activation is measured as task-evoked BOLD response.
Time frame: Neural markers: Collected during fMRI session (single session, ~30 min per participant); Behavioral data: Collected during VR sessions with two visits per participant (throughout study completion, approx. 3 weeks)
Association between neural connectivity and tVNS-induced changes in number of rewards collected
The primary outcome is the association (regression coefficient) quantifying the relationship between neural connectivity and behavioral tVNS response. Behavioral response is defined as the within-subject change in the number of rewards collected during VR foraging under tVNS vs sham. Neural connectivity markers derived from fMRI-testing will be used to assess how neural connectivity explains interindividual variability in behavioral tVNS response.
Time frame: Neural markers: Collected during fMRI session (single session, ~30 min per participant); Behavioral data: Collected during VR sessions with two visits per participant (throughout study completion, approx. 3 weeks)
Associations between baseline cortisol and neural activation
The primary outcome is the association (regression coefficient) quantifying the relationship between cortisol and BOLD response during the effort-trade-off task. Morning serum cortisol will be collected after an overnight fast at the laboratory visit immediately before the MRI session and quantified in nmol/L (expected range approx. 140-690nmol/L). Neural activation is measured as task-evoked BOLD response.
Time frame: Blood draw: Collected before the MRI session; Neural activation: During a single MRI session throughout study completion (approx. 3 weeks)
Association between baseline cortisol and tVNS-induced changes in the number of rewards collected
The primary outcome is the association (regression coefficient) quantifying the relationship between cortisol and behavioral tVNS response. Morning serum cortisol will be collected after an overnight fast at the laboratory visit immediately before the MRI session and quantified in nmol/L (expected range approx. 140-690nmol/L). Behavioral response is defined as the within-subject change in number of rewards collected during VR foraging under active vs sham tVNS.
Time frame: Blood draw: Collected before the MRI session, Behavioral data: Collected during VR sessions with two visits per participant (throughout study completion, approx. 3 weeks)
Association between insulin resistance and BOLD response during the effort-trade-off task
The primary outcome is the association (regression coefficient) quantifying the relationship between the value of insulin resistance and neural activation (BOLD responses) during an effort-trade-off-task. Neural activation is measured as task-evoked BOLD response. Insulin resistance is assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting plasma insulin and glucose concentrations obtained from morning blood samples.
Time frame: Blood samples and neural activation assessed during a single MRI session throughout study completion (approximately 3 weeks)
Association between insulin resistance and tVNS-induced changes in number of rewards collected
The primary outcome is the association (regression coefficient) quantifying the relationship between insulin resistance and behavioral stimulation response during a VR foraging task. Behavioral response to tVNS is measured as the change in the number of rewards collected under threat during a VR foraging task. Insulin resistance is assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting plasma insulin and glucose concentrations obtained from morning blood samples.
Time frame: Behavioral outcomes and biomarker measures assessed throughout study completion (approximately 3 weeks)
BMI (Body-Mass-Index)
Body mass index will be included as a covariate in analyses involving metabolic, neural, and behavioral outcomes.
Time frame: Collected throughout study completion (approximately 3 weeks)
Association between Ecological Momentary Assessments (EMA) and reward learning in the online task
The primary outcome is the association (regression coefficient) quantifying the relationship between mood state and reward learning. Reward learning is measured in the online reward learning task (10 runs with 150 trials each). EMA questions (0-100 Visual Analog Scale) assessing mood (happy - sad) are asked before every run of the online task (10 runs).
Time frame: Assessed online before lab-visits (approximately 10 days)
SHAPS (Snaith-Hamilton Pleasure Scale)
Self-report questionnaire assessing anhedonia severity. Used for grouping participants and associated with behavioral and neural outcomes. Total scores range from 14 to 56 with higher scores reflecting higher anhedonia.
Time frame: Assessed online before lab-visits (approximately 10 days)
TEPS (Temporal Experience of Pleasure Scale)
Questionnaire measuring anticipatory and consummatory pleasure. This outcome will be associated with behavioral and neural outcomes. Total scores range from 18 to 108 with subscales scoring between 10-60 (anticipatory) and 8-48 (consummatory). Higher scores indicate greater hedonic capacity (lower anhedonia) while lower scores represent higher anhedonia symptoms.
Time frame: Assessed online before lab-visits (approximately 10 days)
DARS (Dimensional Anhedonia Rating Scale)
Questionnaire assessing multiple facets of anhedonia. This outcome will be associated with behavioral and neural outcomes. Total scores range from 0 to 68, with subscales scoring between 0-16 (hobbies, food, and social) and 0-20 (sensory). Higher scores indicate greater hedonic capacity (lower anhedonia) while lower scores represent higher anhedonia symptoms.
Time frame: Assessed online before lab-visits (approximately 10 days)
STAI (State-Trait Anxiety Inventory)
Self-report questionnaire assessing trait anxiety. This outcome will be associated with behavioral and neural outcomes. Total scores range from 20 to 80 with higher scores indicating higher anxiety.
Time frame: Assessed online before lab-visits (approximately 10 days)
BDI-II (Beck Depression Inventory-II)
Questionnaire assessing depressive symptoms. Used as an additional symptom dimension. Total scores range from 0 to 63, with higher scores indicating greater depressive symptom severity.
Time frame: Assessed online before lab-visits (approximately 10 days)
Metacognition
Five questions (0-100 Visual Analog Scale) evaluating self-rated performance, self-rated performance compared to the days before, self-rated performance compared to others. Higher scores indicate better self-rated performance.
Time frame: Assessed online before lab-visits (approximately 10 days)
EMA (Ecological Momentary Assessment)
Ecological Momentary Assessments (EMA) using 0-100 Visual Analog Scale, administered repeatedly across online-task and lab sessions to capture current internal states (distraction, satisfaction, physical state, mental well-being, caloric intake, thirst, motivation).
Time frame: Assessed online before lab-visits (approximately 10 days) and during each lab-session throughout study completion (approximately 3 weeks)
Waist-to-hip Ratio
Waist-to-hip ratio will be included as a covariate in analyses involving metabolic, neural, and behavioral outcomes.
Time frame: Collected throughout study completion (approximately 3 weeks)
Cortisol
Morning serum cortisol will be collected after an overnight fast at the laboratory visit immediately before the MRI session and quantified in nmol/L (expected range approx. 140-690nmol/L). Cortisol will be included as a covariate in analyses involving metabolic, neural, and behavioral outcomes.
Time frame: Collected throughout study completion (approximately 3 weeks)
Insulin Resistance
Insulin resistance is assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting plasma insulin and glucose concentrations obtained from morning blood samples. A higher score indicates less insulin sensitivity. HOMA-IR will be included as a covariate in analyses involving metabolic, neural, and behavioral outcomes.
Time frame: Collected throughout study completion (approximately 3 weeks)
STICSA (State-Trait Inventory for Cognitive and Somatic Anxiety)
Questionnaire measuring state and trait anxiety. Used for grouping participants and associated with behavioral and neural outcomes. Total scores range from 21 to 84, with subscales scoring between 11-44 (somatic anxiety) and 10-40 (cognitive anxiety). Higher scores indicate higher anxiety.
Time frame: Assessed online before lab-visits (approximately 10 days)
Plan to share: Yes — After the publication of the key results of the study, anonymized data will be made publicly available (e.g., at osf.org)
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Data will become available after an embargo period of 12 months after completion of the study.
Access criteria: Until the data is publicly available, researchers may contact the lead PI to gain access.
Data sharing details ↗ · neuromadlab.com
Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.
Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 21 months is above that.
Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.